Scientists have identified over 5,000 genetic variations aiding specific cancers, potentially transforming cancer care. Published in Nature Genetics, this research illuminates cancer genetics and unveils new therapeutic targets for combating cancer progression.
BAP1 gene alterations attributed to various cancers
Researchers from the Wellcome Sanger Institute, in collaboration with The Institute of Cancer Research and the University of Cambridge, undertook a comprehensive analysis of the BAP1 gene, crucial for tumor protection. Their findings indicate that about one-fifth of all potential alterations to this gene are pathogenic, significantly elevating the risk for cancers affecting the skin, eye, brain, lung lining, and kidney.
This study stands out not only for its scale but also for its immediate implications for patient care. The publicly accessible findings empower global healthcare providers to leverage this knowledge for more precise diagnoses and personalized treatment strategies. Critically, the study’s inclusive methodology addresses historical gaps in genetics research by encompassing diverse ethnic backgrounds.
Dr. Andrew Waters, lead author from the Wellcome Sanger Institute, emphasized the study’s innovation in exploring gene behavior on a broader scale, enabling deeper insights into how genetic variations drive disease.
The team utilized “saturation genome editing,” modifying all 18,108 possible DNA alterations in the BAP1 gene within cultured human cells, providing a comprehensive understanding of variant impacts on gene function.
Individuals with BAP1 gene more likely to develop cancer
Validation through UK Biobank data reinforced their findings, revealing that individuals carrying harmful BAP1 variants face a more than 10% higher cancer risk compared to the general population. Furthermore, the study uncovered a correlation between specific disruptive BAP1 variants and increased levels of IGF-1, a hormone linked to cancer growth and brain development, suggesting potential avenues for targeted therapies.
Professor Clare Turnbull, clinical lead of the study, underscored the potential benefits for patients and healthcare providers, anticipating enhanced genetic testing accuracy, earlier disease detection, and improved treatment outcomes. For the scientific community, the research showcases the potency of comprehensive genetic analyses in unraveling disease mechanisms, with the identification of IGF-1 as a therapeutic target promising new avenues for cancer treatment development.
